Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses

Jean Luc Raoul, Jordi Bruix, Tim F. Greten, Morris Sherman, Vincenzo Mazzaferro, Philip Hilgard, Hans Scherubl, Max E. Scheulen, Georgios Germanidis, Sophie Dominguez, Sergio Ricci, Andrea Nadel, Marius Moscovici, Dimitris Voliotis, Josep M. Llovet

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background & Aims: Hepatic markers are utilized in many classification systems of patients with hepatocellular carcinoma and, by measuring organ damage and tumor stage, can influence treatment. Moreover, elevated serum concentrations of aminotransferases and alpha-fetoprotein are indicators of poor prognosis in patients with hepatocellular carcinoma. We examined the effects of sorafenib on hepatic markers by performing exploratory subset analyses of the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial in patients categorized by baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, and bilirubin; and by evaluating the effects of sorafenib on bilirubin concentrations during treatment. Methods: Patients (n = 602) were grouped by baseline concentrations of alanine aminotransferase/aspartate aminotransferase (not significantly elevated, mildly elevated, or moderately elevated), alpha-fetoprotein (normal or elevated), and bilirubin (normal or elevated). Bilirubin was measured at baseline and on day 1 of each cycle. Results: Patients with elevated baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin had shorter overall survival (OS) than those with normal baseline concentrations, irrespective of treatment group. No notable differences in safety profiles were observed between patients with normal vs. elevated alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin. Median changes from baseline in bilirubin concentration at the last cycle of treatment were +0.17 and +0.19 mg/dl in the sorafenib and placebo groups, respectively. Conclusions: These subset analyses suggest that sorafenib is safe and effective for hepatocellular carcinoma, irrespective of baseline alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin concentration and that hepatic function remains stable over the course of sorafenib therapy.

Original languageEnglish
Pages (from-to)1080-1088
Number of pages9
JournalJournal of Hepatology
Volume56
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Clinical Protocols
Bilirubin
alpha-Fetoproteins
Aspartate Aminotransferases
Alanine Transaminase
Liver
Hepatocellular Carcinoma
Therapeutics
sorafenib
Transaminases
Placebos
Safety
Survival
Serum
Neoplasms

Keywords

  • Alanine aminotransferase
  • Alpha-fetoprotein
  • Aspartate aminotransferase
  • Bilirubin
  • Hepatic markers
  • Sorafenib

ASJC Scopus subject areas

  • Hepatology

Cite this

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function : SHARP trial subanalyses. / Raoul, Jean Luc; Bruix, Jordi; Greten, Tim F.; Sherman, Morris; Mazzaferro, Vincenzo; Hilgard, Philip; Scherubl, Hans; Scheulen, Max E.; Germanidis, Georgios; Dominguez, Sophie; Ricci, Sergio; Nadel, Andrea; Moscovici, Marius; Voliotis, Dimitris; Llovet, Josep M.

In: Journal of Hepatology, Vol. 56, No. 5, 05.2012, p. 1080-1088.

Research output: Contribution to journalArticle

Raoul, JL, Bruix, J, Greten, TF, Sherman, M, Mazzaferro, V, Hilgard, P, Scherubl, H, Scheulen, ME, Germanidis, G, Dominguez, S, Ricci, S, Nadel, A, Moscovici, M, Voliotis, D & Llovet, JM 2012, 'Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses', Journal of Hepatology, vol. 56, no. 5, pp. 1080-1088. https://doi.org/10.1016/j.jhep.2011.12.009
Raoul, Jean Luc ; Bruix, Jordi ; Greten, Tim F. ; Sherman, Morris ; Mazzaferro, Vincenzo ; Hilgard, Philip ; Scherubl, Hans ; Scheulen, Max E. ; Germanidis, Georgios ; Dominguez, Sophie ; Ricci, Sergio ; Nadel, Andrea ; Moscovici, Marius ; Voliotis, Dimitris ; Llovet, Josep M. / Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function : SHARP trial subanalyses. In: Journal of Hepatology. 2012 ; Vol. 56, No. 5. pp. 1080-1088.
@article{bd3a821676dc4720b890a5cac33b728e,
title = "Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses",
abstract = "Background & Aims: Hepatic markers are utilized in many classification systems of patients with hepatocellular carcinoma and, by measuring organ damage and tumor stage, can influence treatment. Moreover, elevated serum concentrations of aminotransferases and alpha-fetoprotein are indicators of poor prognosis in patients with hepatocellular carcinoma. We examined the effects of sorafenib on hepatic markers by performing exploratory subset analyses of the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial in patients categorized by baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, and bilirubin; and by evaluating the effects of sorafenib on bilirubin concentrations during treatment. Methods: Patients (n = 602) were grouped by baseline concentrations of alanine aminotransferase/aspartate aminotransferase (not significantly elevated, mildly elevated, or moderately elevated), alpha-fetoprotein (normal or elevated), and bilirubin (normal or elevated). Bilirubin was measured at baseline and on day 1 of each cycle. Results: Patients with elevated baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin had shorter overall survival (OS) than those with normal baseline concentrations, irrespective of treatment group. No notable differences in safety profiles were observed between patients with normal vs. elevated alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin. Median changes from baseline in bilirubin concentration at the last cycle of treatment were +0.17 and +0.19 mg/dl in the sorafenib and placebo groups, respectively. Conclusions: These subset analyses suggest that sorafenib is safe and effective for hepatocellular carcinoma, irrespective of baseline alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin concentration and that hepatic function remains stable over the course of sorafenib therapy.",
keywords = "Alanine aminotransferase, Alpha-fetoprotein, Aspartate aminotransferase, Bilirubin, Hepatic markers, Sorafenib",
author = "Raoul, {Jean Luc} and Jordi Bruix and Greten, {Tim F.} and Morris Sherman and Vincenzo Mazzaferro and Philip Hilgard and Hans Scherubl and Scheulen, {Max E.} and Georgios Germanidis and Sophie Dominguez and Sergio Ricci and Andrea Nadel and Marius Moscovici and Dimitris Voliotis and Llovet, {Josep M.}",
year = "2012",
month = "5",
doi = "10.1016/j.jhep.2011.12.009",
language = "English",
volume = "56",
pages = "1080--1088",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function

T2 - SHARP trial subanalyses

AU - Raoul, Jean Luc

AU - Bruix, Jordi

AU - Greten, Tim F.

AU - Sherman, Morris

AU - Mazzaferro, Vincenzo

AU - Hilgard, Philip

AU - Scherubl, Hans

AU - Scheulen, Max E.

AU - Germanidis, Georgios

AU - Dominguez, Sophie

AU - Ricci, Sergio

AU - Nadel, Andrea

AU - Moscovici, Marius

AU - Voliotis, Dimitris

AU - Llovet, Josep M.

PY - 2012/5

Y1 - 2012/5

N2 - Background & Aims: Hepatic markers are utilized in many classification systems of patients with hepatocellular carcinoma and, by measuring organ damage and tumor stage, can influence treatment. Moreover, elevated serum concentrations of aminotransferases and alpha-fetoprotein are indicators of poor prognosis in patients with hepatocellular carcinoma. We examined the effects of sorafenib on hepatic markers by performing exploratory subset analyses of the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial in patients categorized by baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, and bilirubin; and by evaluating the effects of sorafenib on bilirubin concentrations during treatment. Methods: Patients (n = 602) were grouped by baseline concentrations of alanine aminotransferase/aspartate aminotransferase (not significantly elevated, mildly elevated, or moderately elevated), alpha-fetoprotein (normal or elevated), and bilirubin (normal or elevated). Bilirubin was measured at baseline and on day 1 of each cycle. Results: Patients with elevated baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin had shorter overall survival (OS) than those with normal baseline concentrations, irrespective of treatment group. No notable differences in safety profiles were observed between patients with normal vs. elevated alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin. Median changes from baseline in bilirubin concentration at the last cycle of treatment were +0.17 and +0.19 mg/dl in the sorafenib and placebo groups, respectively. Conclusions: These subset analyses suggest that sorafenib is safe and effective for hepatocellular carcinoma, irrespective of baseline alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin concentration and that hepatic function remains stable over the course of sorafenib therapy.

AB - Background & Aims: Hepatic markers are utilized in many classification systems of patients with hepatocellular carcinoma and, by measuring organ damage and tumor stage, can influence treatment. Moreover, elevated serum concentrations of aminotransferases and alpha-fetoprotein are indicators of poor prognosis in patients with hepatocellular carcinoma. We examined the effects of sorafenib on hepatic markers by performing exploratory subset analyses of the Sorafenib HCC Assessment Randomized Protocol (SHARP) trial in patients categorized by baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, and bilirubin; and by evaluating the effects of sorafenib on bilirubin concentrations during treatment. Methods: Patients (n = 602) were grouped by baseline concentrations of alanine aminotransferase/aspartate aminotransferase (not significantly elevated, mildly elevated, or moderately elevated), alpha-fetoprotein (normal or elevated), and bilirubin (normal or elevated). Bilirubin was measured at baseline and on day 1 of each cycle. Results: Patients with elevated baseline concentrations of alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin had shorter overall survival (OS) than those with normal baseline concentrations, irrespective of treatment group. No notable differences in safety profiles were observed between patients with normal vs. elevated alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin. Median changes from baseline in bilirubin concentration at the last cycle of treatment were +0.17 and +0.19 mg/dl in the sorafenib and placebo groups, respectively. Conclusions: These subset analyses suggest that sorafenib is safe and effective for hepatocellular carcinoma, irrespective of baseline alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin concentration and that hepatic function remains stable over the course of sorafenib therapy.

KW - Alanine aminotransferase

KW - Alpha-fetoprotein

KW - Aspartate aminotransferase

KW - Bilirubin

KW - Hepatic markers

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84859726758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859726758&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2011.12.009

DO - 10.1016/j.jhep.2011.12.009

M3 - Article

C2 - 22245896

AN - SCOPUS:84859726758

VL - 56

SP - 1080

EP - 1088

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 5

ER -